FGF21 is an independent risk factor for T2DM patients with CAS or HP, and is positively correlated with obesity-related index (BMI), and the degree of AS index (IMT), indicating that FGF21 is increased in the condition of obesity, CAS, HP and other cardiovascular and metabolic diseases, and is a potent regulator of glucose and lipid metabolism. This evidence concerns the gene FGF21 and obesity due to melanocortin 4 receptor deficiency.